For a decade, CAR-T cell therapy has been defined by its success in treating liquid cancers, turning the body’s own immune cells into precision instruments for hunting tumors. Now, a new frontier is opening in the treatment of autoimmune disorders. Kyverna Therapeutics announced this week that it plans to seek FDA approval for a personalized cell therapy targeting stiff person syndrome (SPS), a rare and debilitating neurological condition characterized by muscle stiffness and painful spasms.
The treatment works by essentially rebooting the patient’s internal defenses. By engineering T cells to deplete B cells—the primary drivers of the autoimmune response—Kyverna aims to halt the progression of SPS and restore mobility. Early study results presented on Tuesday suggest the therapy significantly reduced disability in patients, offering a potential breakthrough for a condition that currently lacks a dedicated, approved treatment.
If the FDA grants approval following Kyverna’s mid-year submission, the therapy would represent a historic milestone: the first CAR-T treatment to reach the market for an autoimmune disease of any kind. This transition reflects a broader strategic shift in biotechnology, as researchers increasingly look to cellular engineering not just to kill cancer, but to recalibrate the complex and often volatile systems of human immunity.
With reporting from STAT News.
Source · STAT News (Biotech)
